The RTS,S/AS01 malaria vaccine is being introduced sub-nationally in phased pilot introductions through the EPI programmes in Malawi Ghana and Kenya. Vaccine introduction is by the respective MoH in selected areas randomly assigned to receive the vaccine at the beginning of the pilots. In the context of this programmatic activity, the Malaria Vaccine Pilot Evaluation (MVPE) registered here as observational evaluations during early vaccine introduction, include a series of 3 household surveys, and sentinel hospital and community mortality surveillance, building on routine systems. These observational evaluations will measure: 1. The programmatic feasibility of delivering a 4 dose schedule; 2. Safety in routine use, with focus on cerebral malaria and meningitis; 3. The impact of the malaria vaccine in routine use on severe malaria and all-cause mortality
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The number of deaths of any cause
Timeframe: From 0 to 46 months after vaccination starts
Number of children admitted with a diagnosis of probable and confirmed meningitis cases
Timeframe: From 0 to 30 months after vaccination starts
Number of children admitted with a diagnosis of cerebral malaria
Timeframe: From 0 to 30 months after vaccination starts
Number of children aged 12-23 months who have completed the primary series (the 3 dose regime) of the malaria vaccine
Timeframe: At 18 months after vaccination starts
Number of children aged 27-38 months who have completed the 4th dose of the malaria vaccine
Timeframe: At 30 months after vaccination starts